Perspective Therapeutics
Price & Volume
Stats
See more52W Range | $1.95-$6.16 |
Market Cap | $360.7M |
Shares Short | 23M |
Financials
See moreRevenue (12 Mos) | $409,000 |
Revenue Growth (YoY) | -72.1% |
Gross Profit (12 Mos) | -$95.7M |
Diluted EPS | -$1.28 |
News
See moreYahoo Finance • last month
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Yahoo Finance • last month
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
Yahoo Finance • 2 months ago
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
Yahoo Finance • 2 months ago
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials
About
CEO | Mr. Johan M. Spoor |
CFO | Mr. Joel David Sendek |
Address | 2401 Elliott Avenue, Seattle, WA, United States, 98121 |
Sector | Healthcare |
Industry | Medical Devices |
Full-Time Employees | 163 |